Breast Cancer Metastatic Clinical Trials

43 recruitingLast updated: June 17, 2026

There are 43 actively recruiting breast cancer metastatic clinical trials across 13 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3. Top locations include Shanghai, Shanghai Municipality, China, New York, New York, United States, Milan, Italy. Updated daily from ClinicalTrials.gov.


Breast Cancer Metastatic Trials at a Glance

43 actively recruiting trials for breast cancer metastatic are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 2 with 16 trials, with the heaviest enrollment activity in Shanghai, New York, and Milan. Lead sponsors running breast cancer metastatic studies include Fudan University, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, and European Institute of Oncology.

Browse breast cancer metastatic trials by phase

Treatments under study

About Breast Cancer Metastatic Clinical Trials

Looking for clinical trials for Breast Cancer Metastatic? There are currently 40 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Breast Cancer Metastatic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Breast Cancer Metastatic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 43 trials

Recruiting
Phase 2

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Breast Cancer Metastatic
ALX Oncology Inc.120 enrolled44 locationsNCT07007559
Recruiting
Phase 1

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

Breast CancerBreast Cancer MetastaticMetastatic Breast Cancer+5 more
Memorial Sloan Kettering Cancer Center28 enrolled7 locationsNCT06678269
Recruiting

HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity

Breast Cancer Metastatic
Fudan University100 enrolled1 locationNCT07586215
Recruiting
Phase 2

Trial of Trastuzumab Deruxtecan in Previously Treated HER2

Breast Cancer Metastatic
Yale University40 enrolled2 locationsNCT06750484
Recruiting
Not Applicable

Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device

Breast Cancer MetastaticBreast Cancer Early Stage Breast Cancer (Stage 1-3)Breast Cancer Invasive
ScreenCell93 enrolled1 locationNCT06807502
Recruiting
Phase 1

A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer.

Breast CancerBreast Cancer Metastatic
ExpreS2ion Biotechnologies40 enrolled3 locationsNCT06746688
Recruiting
Phase 3

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Breast CancerBreast Cancer MetastaticMetastatic Breast Cancer+2 more
BriaCell Therapeutics Corporation404 enrolled79 locationsNCT06072612
Recruiting
Phase 1Phase 2

HER2-PET Imaging in HER2-low Breast Cancers

Breast Cancer Metastatic
Centre de recherche du Centre hospitalier universitaire de Sherbrooke40 enrolled1 locationNCT06732336
Recruiting
Phase 1Phase 2

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Breast CancerBreast Cancer MetastaticOvarian Cancer+6 more
Incyclix Bio150 enrolled18 locationsNCT05735080
Recruiting

PIK3CA Mutational Status Assessment

Breast Cancer Metastatic
European Institute of Oncology100 enrolled1 locationNCT06706570
Recruiting

Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer (mBC) Patients,

Breast Cancer Metastatic
European Institute of Oncology80 enrolled1 locationNCT06762483
Recruiting
Phase 1

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

Breast Cancer MetastaticLocally Advanced Breast Cancer (LABC)Malignant Neoplasm of Breast
Calibr, a division of Scripps Research20 enrolled5 locationsNCT06878248
Recruiting
Not Applicable

Nutrition Awareness Among Women With Non-Metastatic Breast Cancer

Breast CancerBreast Cancer Metastatic
UNC Lineberger Comprehensive Cancer Center200 enrolled1 locationNCT07389967
Recruiting
Phase 1

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

Breast Cancer MetastaticHER2-Negative Breast CarcinomaPancreatic Cancer+17 more
General Oncology, Inc.24 enrolled2 locationsNCT04150042
Recruiting
Phase 1Phase 2

Target-specific immunoPET Imaging of Breast Cancer

Breast CancerBreast Cancer MetastaticBreast Neoplasms
RenJi Hospital200 enrolled1 locationNCT06715826
Recruiting
Phase 1

SLV-154 Treatment of Metastatic Solid Tumors

Breast Cancer MetastaticOvarian CancerEndometrial Cancer+7 more
Solve Therapeutics70 enrolled9 locationsNCT06771219
Recruiting
Phase 1Phase 2

A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

Breast Cancer MetastaticRenal Cell Carcinoma MetastaticProstate Cancer Metastatic+2 more
Kidney Cancer Research Bureau58 enrolled5 locationsNCT07292168
Recruiting
Phase 1

Sapu003 in Advanced mTOR-sensitive Solid Tumors

Breast Cancer MetastaticNeuroendocrine TumorsRenal Cell Carcinoma (RCC)+2 more
SAPU NANO (US) LLC27 enrolled1 locationNCT07369505
Recruiting

To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.

Breast Cancer Metastatic
Zhejiang Cancer Hospital200 enrolled1 locationNCT06784921
Recruiting
Phase 1

Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer

HER2-negative Breast CancerBreast Cancer Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute18 enrolled1 locationNCT06691035